{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:08:22Z","timestamp":1779916102722,"version":"3.53.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U2RTW010673"],"award-info":[{"award-number":["U2RTW010673"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW011818"],"award-info":[{"award-number":["D43TW011818"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-035308"],"award-info":[{"award-number":["INV-035308"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000953","name":"Alliance for Cancer Gene Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2025.127680","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T19:48:35Z","timestamp":1756756115000},"page":"127680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021\u2013February 2023"],"prefix":"10.1016","volume":"77","author":[{"given":"Saidou","family":"Balam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fousseyni","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bourama","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drissa","family":"Konate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimata A.","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Housseini","family":"Dolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anou Moise","family":"Somboro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousmane","family":"Kodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antieme Combo Georges","family":"Togo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassirou","family":"Diarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Incandela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdouramane","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salimata","family":"Kante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merepen dite Agnes","family":"Guindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bourema","family":"Kouriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaya Ibrahim","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousmane","family":"Faye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seydou","family":"Doumbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamadou","family":"Diakite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127680_bb0005","author":"Edouard"},{"key":"10.1016\/j.vaccine.2025.127680_bb0010","author":"Organization WH"},{"key":"10.1016\/j.vaccine.2025.127680_bb0015","author":"Edouard"},{"key":"10.1016\/j.vaccine.2025.127680_bb0020","doi-asserted-by":"crossref","unstructured":"Traor\u00e9 B, Guindo MA, Konat\u00e9 D, Kan\u00e9 F, Incandela NC, Traore A, et al. Seroprevalence of SARS-CoV-2 antibodies and associated factors in Bamako, Mali: A population-based cross-sectional study in September 2022. Influenza Other Respiratory Viruses. 2024;18(7):e13343. Epub 2024\/07\/24. doi: https:\/\/doi.org\/10.1111\/irv.13343. PubMed PMID: 39044355; PubMed Central PMCID: PMCPMC11300109.","DOI":"10.1111\/irv.13343"},{"key":"10.1016\/j.vaccine.2025.127680_bb0025","doi-asserted-by":"crossref","unstructured":"Bekliz M, Adea K, Vetter P, Eberhardt C.S, Hosszu-Fellous K, Vu D.L, et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat Commun 2022;13(1):3840. doi: https:\/\/doi.org\/10.1038\/s41467-022-31556-1.","DOI":"10.1038\/s41467-022-31556-1"},{"key":"10.1016\/j.vaccine.2025.127680_bb0030","doi-asserted-by":"crossref","unstructured":"Brunner W.M, Freilich D, Victory J, Krupa N, Scribani M.B. Jenkins P, et al. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis. 2022;123:183\u201391. Epub 2022\/09\/01. doi: https:\/\/doi.org\/10.1016\/j.ijid.2022.08.022. PubMed PMID: 36044963; PubMed Central PMCID: PMCPMC9420538.","DOI":"10.1016\/j.ijid.2022.08.022"},{"issue":"10324","key":"10.1016\/j.vaccine.2025.127680_bb0035","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127680_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003991","article-title":"Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study","volume":"19","author":"van Gils","year":"2022","journal-title":"PLoS Med"},{"issue":"7839","key":"10.1016\/j.vaccine.2025.127680_bb0045","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127680_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.981693","article-title":"Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay","volume":"13","author":"D\u2019Apice","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127680_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.856033","article-title":"Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas","volume":"13","author":"Traor\u00e9","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127680_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901217","article-title":"Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection","volume":"13","author":"Wieczorek","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127680_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31778","article-title":"Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection","volume":"5","author":"Gilboa","year":"2022","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127680_bb0070","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerg Microb Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127680_bb0075","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jinf.2022.04.018","article-title":"Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial","volume":"84","author":"Liu","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2025.127680_bb0080","unstructured":"CDC. Understanding How COVID-19 Vaccines Work. https:\/\/rbgy\/ud1iop. Accessed: April 05, 2024."},{"issue":"3","key":"10.1016\/j.vaccine.2025.127680_bb0085","first-page":"269","article-title":"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac\u00ae, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria\u00ae, Oxford-AstraZeneca) vaccinations in health care workers","volume":"40","author":"Jantarabenjakul","year":"2022","journal-title":"Asian Pacific J Allergy Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127680_bb0090","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Human Vacc Immunother"},{"key":"10.1016\/j.vaccine.2025.127680_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1031852","article-title":"Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals","volume":"13","author":"Goh","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127680_bb0100","unstructured":"Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet (London, England). 2021;398(10318):2258\u201376. Epub 2021\/12\/06. doi: https:\/\/doi.org\/10.1016\/s0140-6736(21)02717-3.PubMed PMID: 34863358; PubMed Central PMCID: PMCPMC8639161."},{"key":"10.1016\/j.vaccine.2025.127680_bb0105","doi-asserted-by":"crossref","unstructured":"Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H, et al. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA. 2022;327(4):341\u20139. Epub 2022\/01\/11. doi: https:\/\/doi.org\/10.1001\/jama.2021.23641. PubMed PMID: 35006256; PubMed Central PMCID: PMCPMC8749710.","DOI":"10.1001\/jama.2021.23641"},{"key":"10.1016\/j.vaccine.2025.127680_bb0110","doi-asserted-by":"crossref","unstructured":"Davidovic T, Schimpf J, Abbassi-Nik A, Stockinger R, Sprenger-M\u00e4hr H, Lhotta K, et al. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Front Immunol. 2022;13:907615. Epub 2022\/07\/12. doi: https:\/\/doi.org\/10.3389\/fimmu.2022.907615. PubMed PMID: 35812459; PubMed Central PMCID: PMCPMC9261096.","DOI":"10.3389\/fimmu.2022.907615"},{"key":"10.1016\/j.vaccine.2025.127680_bb0115","unstructured":"Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet (London, England). 2021;398(10303):856\u201369. Epub 2021\/08\/10. doi: https:\/\/doi.org\/10.1016\/s0140-6736(21)01694-9. PubMed PMID: 34370971; PubMed Central PMCID: PMCPMC8346248."},{"key":"10.1016\/j.vaccine.2025.127680_bb0120","doi-asserted-by":"crossref","unstructured":"Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet (London, England). 2022;399(10319):36\u201349. Epub 2021\/12\/10. doi: https:\/\/doi.org\/10.1016\/s0140-6736(21)02718-5. PubMed PMID: 34883053; PubMed Central PMCID: PMCPMC8648333.","DOI":"10.1016\/S0140-6736(21)02718-5"},{"key":"10.1016\/j.vaccine.2025.127680_bb0125","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet (London, England). 2021;396(10267):1979\u201393. Epub 2020\/11\/23. doi: https:\/\/doi.org\/10.1016\/s0140-6736(20)32466-1. PubMed PMID: 33220855; PubMed Central PMCID: PMCPMC7674972."},{"key":"10.1016\/j.vaccine.2025.127680_bb0130","author":"Administration FaD"},{"key":"10.1016\/j.vaccine.2025.127680_bb0135","unstructured":"Bio-Rad. Platelia SARS-CoV-2 Total Ab. https:\/\/shorturlat\/1fbR1. Accessed: April 21, 2023."},{"key":"10.1016\/j.vaccine.2025.127680_bb0140","first-page":"12","article-title":"SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants","author":"Mart\u00ednez-Flores","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127680_bb0145","article-title":"Adapting UNITY study protocols to COVID-19 vaccine rollout","volume":"1","author":"Organization WH","year":"2021","journal-title":"Version"},{"key":"10.1016\/j.vaccine.2025.127680_bb0150","doi-asserted-by":"crossref","unstructured":"Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, et al. Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. Open forum infectious diseases. 2022;9(2):ofab632. Epub 2022\/02\/02. doi: https:\/\/doi.org\/10.1093\/ofid\/ofab632. PubMed PMID: 35103246; PubMed Central PMCID: PMCPMC8755308.","DOI":"10.1093\/ofid\/ofab632"},{"key":"10.1016\/j.vaccine.2025.127680_bb0155","unstructured":"Biobase. Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit (Fluorescence PCR). https:\/\/shorturlat\/34Jfy. Accessed: December 28, 2023."},{"key":"10.1016\/j.vaccine.2025.127680_bb0160","doi-asserted-by":"crossref","unstructured":"Di Resta C FD, Vigan\u00f2 M, Moro M, Sabetta E, Minerva M, Ambrosio A, Locatelli M, Tomaiuolo R. The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination\u2014An analysis of serological response and side effects. Vaccines. 2021;9(5):522. PubMed PMID: doi:https:\/\/doi.org\/10.3390\/vaccines9050522.","DOI":"10.3390\/vaccines9050522"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127680_bb0165","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.vaccine.2021.11.081","article-title":"SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study","volume":"40","author":"Herzberg","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127680_bb0170","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, et al. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study. Cancer cell. 2022;40(6):581\u20133. Epub 2022\/05\/06. doi: https:\/\/doi.org\/10.1016\/j.ccell.2022.04.016. PubMed PMID: 35512712; PubMed Central PMCID: PMCPMC9040439.","DOI":"10.1016\/j.ccell.2022.04.016"},{"key":"10.1016\/j.vaccine.2025.127680_bb0175","doi-asserted-by":"crossref","unstructured":"Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences and age. Womens Health (Lond). 2021;17:17455065211022262. Epub 2021\/06\/08. doi: https:\/\/doi.org\/10.1177\/17455065211022262. PubMed PMID: 34096383; PubMed Central PMCID: PMCPMC8188967.","DOI":"10.1177\/17455065211022262"},{"key":"10.1016\/j.vaccine.2025.127680_bb0180","doi-asserted-by":"crossref","unstructured":"Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1):e044640. Epub 2021\/01\/13. doi: https:\/\/doi.org\/10.1136\/bmjopen-2020-044640. PubMed PMID: 33431495; PubMed Central PMCID: PMCPMC7802392.","DOI":"10.1136\/bmjopen-2020-044640"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127680_bb0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s43856-023-00277-x","article-title":"Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity","volume":"3","author":"Dietz","year":"2023","journal-title":"Commun Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127680_bb0190","doi-asserted-by":"crossref","DOI":"10.4110\/in.2019.19.e37","article-title":"Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity","volume":"19","author":"Oh","year":"2019","journal-title":"Immune Network"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127680_bb0195","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s43587-021-00114-7","article-title":"SARS-CoV-2, COVID-19 and the Ageing Immune System","volume":"1","author":"Bartleson","year":"2021","journal-title":"Nat Aging"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127680_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010211","article-title":"Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination","volume":"17","author":"Almendro-V\u00e1zquez","year":"2022","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127680_bb0205","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1038\/s41467-022-33550-z","article-title":"Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study","volume":"13","author":"Shrotri","year":"2022","journal-title":"Nat Commun"},{"issue":"68","key":"10.1016\/j.vaccine.2025.127680_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"issue":"600","key":"10.1016\/j.vaccine.2025.127680_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection","volume":"13","author":"Greaney","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127680_bb0220","article-title":"High number and specific comorbidities could impact the immune response in COVID-19 patients","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.vaccine.2025.127680_bb0225","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1099\/jgv.0.001439","article-title":"The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection","volume":"101","author":"Kellam","year":"2020","journal-title":"J Gener Virol"},{"key":"10.1016\/j.vaccine.2025.127680_bb0230","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Al\u00f3s L, Armenteros, J. J. A., Madsen, J. R., Hansen, C. B., Jarlhelt, I., Hamm, S. R., ... & Garred, P. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors Nat Commun 2022;13(1):1614. doi: https:\/\/doi.org\/10.1038\/s41467-022-29225-4.","DOI":"10.1038\/s41467-022-29225-4"},{"key":"10.1016\/j.vaccine.2025.127680_bb0235","article-title":"Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity","author":"Truong","year":"2021","journal-title":"medRxiv: preprint Server for Health Sciences"},{"key":"10.1016\/j.vaccine.2025.127680_bb0240","article-title":"Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis","volume":"377","author":"Wing Ying","year":"2022","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127680_bb0245","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"New Eng J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127680_bb0250","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.26335","article-title":"Durability of heterologous and homologous COVID-19 vaccine boosts","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127680_bb0255","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.16797","article-title":"Association between ABO blood groups and risk of SARS-CoV-2 pneumonia","volume":"190","author":"Li","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2025.127680_bb0260","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cca.2020.06.026","article-title":"Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19","volume":"509","author":"Wu","year":"2020","journal-title":"Clin Chim Acta; Int J Clin Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127680_bb0265","first-page":"54","article-title":"Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood transfusion =","volume":"19","author":"Mu\u00f1iz-Diaz","year":"2021","journal-title":"Trasfusione del sangue"},{"key":"10.1016\/j.vaccine.2025.127680_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105658","article-title":"ABO blood group and link to COVID-19: A comprehensive review of the reported associations and their possible underlying mechanisms","volume":"169","author":"Pereira","year":"2022","journal-title":"Microbial Pathogenesis"},{"key":"10.1016\/j.vaccine.2025.127680_bb0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tacc.2020.08.005","article-title":"Corona Covid-19 virus and severe hypoxia in young patients without underlying disease: high prevalence rate with blood group A","volume":"34","author":"Solhpour","year":"2020","journal-title":"Trends Anaesthesia Crit Care"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127680_bb0280","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/glycob\/cwn093","article-title":"Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies","volume":"18","author":"Guillon","year":"2008","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2025.127680_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.882477","article-title":"ABO blood system and COVID-19 susceptibility: anti-a and anti-b antibodies are the key points","volume":"9","author":"Tamayo-Velasco","year":"2022","journal-title":"Front Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:31:48Z","timestamp":1779913908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":57,"alternative-id":["S0264410X25009776"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127680","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021\u2013February 2023","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127680"}}